🚨 Latest #Phase 3 Trial Update! 🔷 The Phase III EMERALD-3 trial showed that Imfinzi® plus Imjudo® with Lenvatinib and TACE greatly improved progression-free survival in embolisation-eligible unresectable liver cancer. This multi-modal approach shows enhanced disease control and delayed progression.

👉️ Take the Basal Cell Carcinoma quiz now - bit.ly/BCCA_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can complete in minutes. ✅️ Navigate treatment sequencing in locally advanced and HHI-refractory BCC

🚨 Latest #Oncology Update! 🔷 The European Commission has approved KEYTRUDA in combination with Paclitaxel ± Bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma. This approval gives treatment options for patients who have received one or systemic therapies.

This post is not intended for the U.S. audience. 👉️ Take the ESR1 Mutations: Relevance in Breast Cancer & Potential Therapeutic Implications now - bit.ly/ESR1_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can finish in mins

🚨 Latest #Oncology Update! 🔷 Real-world evidence generated using Guardant Health’s InfinityAI platform supported the approval of ENHERTU® (Trastuzumab deruxtecan) in Japan for previously treated HER2-positive advanced solid tumors, complementing data from DESTINY clinical trials.

This post is not intended for the U.S. audience. 👉️ Take the ESR1 Mutations: Relevance in Breast Cancer & Potential Therapeutic Implications now - bit.ly/ESR1_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals a fast, high-yield knowledge check you can finish in mins

🚨 Latest #Oncology Update! 🔷 EMA has recommended Imdylltra (tarlatamab) for relapsed ES-SCLC after platinum therapy. Phase 3 data showed improved OS of 13.6 vs 8.3 months, reducing risk of death by 40%.

🚨 Latest #FDA Update! 🔷 The FDA has approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with esophageal and gastroesophageal junction (GEJ) carcinoma, enabling identification of patients with PD-L1 CPS ≥1 who may benefit from pembrolizumab.

🚨 Latest #FDA Update! 🔷 The FDA has approved Lifyorli™ (Relacorilant) in combination with Nab-paclitaxel for patients with platinum-resistant ovarian cancer, introducing a novel treatment option in a difficult-to-treat setting.

🚨 Latest #FDA Update! 🔷 TRIANA Biomedicines’ TRI-611 has received U.S. FDA Fast Track designation for the treatment of ALK-positive non-small cell lung cancer. The designation highlights the therapy’s potential to address an unmet need in targeted lung cancer treatment.

🚨 Latest #Phase 3 Update! 🔷 A Phase 3 randomized trial compared transdermal estradiol (tE2) patches with LHRH agonists in men with locally advanced prostate cancer. The study showed comparable 3-year metastasis-free survival (87.1% vs 85.9%; HR 0.96), meeting the predefined non-inferiority margin.

🚨 Latest #Phase3 Update! 🔷 A Phase 3 trial evaluated adjuvant Atezolizumab plus mFOLFOX6 in patients with resected stage III dMMR colon cancer, compared with mFOLFOX6 alone. The study assessed whether adding immunotherapy could enhance disease-free survival (DFS) outcomes.

🚨 Latest #Oncology Update! 🔷 GSK plc’s investigational B7-H3-targeted antibody-drug conjugate, Risvutatug rezetecan, has received Orphan Drug Designation in Japan for the treatment of Small-Cell Lung Cancer, supported by phase 1 ARTEMIS-001 trial.

🚨 Latest #Approval Update! 🔷 Bristol Myers Squibb has gained expanded U.S. and EU approvals for Opdivo® (nivolumab) in classical Hodgkin lymphoma. New indications include nivolumab-based combinations for both previously untreated and relapsed/refractory patients.

👉️ Take the Multiple Myeloma ONCO-IQ quiz now — bit.ly/MUMY_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes. ✅️ Apply evidence from landmark trials to myeloma treatment sequencing

👉️ Take the Multiple Myeloma ONCO-IQ quiz now — bit.ly/MUMY_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

🚨 Latest #Phase 3 Update! 🔷 The combination of TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improves radiographic progression-free survival in patients with metastatic prostate cancer. This highlights the potential of targeted combination therapy to delay disease progression.

🚨 Latest #Phase 3 Update! 🔷 HUTCHMED has initiated a Phase III clinical trial evaluating HMPL-760 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study aims to assess the efficacy and safety of a population with significant unmet treatment needs.

🚨 Latest #Phase 3 Update! 🔷 The Phase 3 BRIGHT-2 trial evaluates the efficacy of Bireociclib combined with Fulvestrant in patients with breast cancer who have progressed after endocrine therapy. The study explores a targeted strategy to overcome endocrine resistance and improve progression outcome

🚨 Latest #FDA Update! 🔷 The FDA has approved Myriad Genetics' MyChoice CDx as the only companion diagnostic for Zejula (Niraparib) in advanced ovarian cancer, enabling precise identification of HRD-positive patients who stand to benefit most from PARP inhibitor therapy.

🚨 Latest #Phase3 Update! 🔷 Vergent Bioscience has initiated the Phase 3 VISUALIZE 2 trial evaluating Abenacianine (VGT-309) for real-time tumor visualization during lung cancer surgery, aiming to improve intraoperative detection and identification of malignant tissue.

🚨 Latest #Phase3 Update! 🔷 An international phase III randomized trial, EURO EWING 2012 (EE2012), evaluated adding zoledronic acid to consolidation chemotherapy in patients with Ewing sarcoma. The study examined whether bone-targeted therapy could improve clinical outcomes.

🚨 Latest #Phase3 Update! 🔷 In the phase 3 COMPASSION-16 trial, adding Cadonilimab to first-line chemotherapy (with or without Bevacizumab) delivered consistent progression-free survival (PFS) benefit across all tested subgroups, with a median follow-up of 25.6 months.

🚨 Latest #Phase3 Update! 🔷 In the Phase III LEAP-010 trial, lenvatinib + pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in first-line PD-L1 CPS ≥1 R/M HNSCC.

👉️ Take the Medulloblastoma ONCO-IQ quiz now — bit.ly/MEDB_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals — a fast, high-yield knowledge check you can complete in minutes. ✅️ Apply clinical and molecular risk stratification in medulloblastoma

🚨 Latest #Phase3 Update! 🔷 In a Phase III randomized trial (RECITE), Romiplostim significantly reduced chemotherapy dose modifications due to chemotherapy-induced thrombocytopenia (CIT) in patients receiving oxaliplatin-based chemotherapy for gastrointestinal cancers.

🚨 Latest #FDA Update! 🔷 Cairn Surgical has submitted a De Novo 510(k) pre-market application to the FDA for its breast cancer locator system. The technology is designed to help surgeons more precisely identify tumor locations during breast cancer procedures.

🚨 Latest #Oncology Study Update! 🔷 The PSMA-PET PROMISE (PPP3) international registry study explores new prostate cancer risk groups defined using PSMA-PET imaging, aiming to improve disease stratification.

🚨 Latest #Phase3 Trial Update! 🔷 The Phase III CAMPASS trial evaluates benmelstobart plus anlotinib versus pembrolizumab as first-line therapy in patients with PD-L1–positive advanced NSCLC.

🚨 Latest #Phase3 Trial Update! 🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.

🚨 Latest #Phase3 Update! 🔷 A biomarker analysis from the Phase III CONTINUUM and DIPPER trials developed a machine-learning classifier identifying three metabolic subtypes (MS1–MS3) in locoregionally advanced nasopharyngeal carcinoma (NPC) to better predict response to immunotherapy.

🚨 Latest #FDAReview Update! 🔷 ENHERTU® (Trastuzumab Deruxtecan) has been granted Priority Review by the U.S. FDA as a potential post-neoadjuvant treatment for patients with HER2-positive early breast cancer, highlighting its potential role in addressing residual disease following initial therapy.

🚨 Latest #EC_Approval Update! 🔷 The European Commission has approved Retifanlimab (Zynyz) in combination with Carboplatin and Paclitaxel for the first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC)

🚨 Latest #Phase 3 Update! 🔷 Roche reported Phase III persevERA results evaluating Giredestrant + Palbociclib in ER-positive, HER2-negative advanced breast cancer. The trial did not meet its primary endpoint of significantly improving progression free survival (PFS) vs Letrozole + Palbociclib.

👉️ Take this week’s ONCO-IQ quiz: EGFR Inhibitor–Associated Skin Toxicities – bit.ly/EGFR_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals a fast, high-yield knowledge check you can complete in mins ✅️ Understand the mechanisms behind EGFRi–associated skin toxicities

🚨 Latest #FDAApproval Update! 🔷 The FDA has approved teclistamab in combination with daratumumab hyaluronidase-fihj for patients with relapsed or refractory multiple myeloma, expanding treatment options in the later-line setting.

🚨 Latest #Approval Update! 🔷 Pirtobrutinib (Jaypirca) receives approval from China’s National Medical Products Administration for relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

🚨 Latest #FDA Approval Update! 🔷 The FDA has accepted the New Drug Application (NDA) for Rusfertide, a first-in-class hepcidin mimetic and granted Priority Review, accelerating its regulatory pathway in polycythemia vera.

🚨 Latest #Phase3 Trial Update! 🔷 Adjuvant treatment with KEYTRUDA® (pembrolizumab) plus WELIREG® (belzutifan) reduced the risk of disease recurrence or death by 28% compared to KEYTRUDA® alone in certain patients with earlier-stage Renal cell carcinoma (RCC).

👉️ Take the Genitourinary Cancers ONCO-IQ quiz in collaboration with IUCS now —https://bit.ly/GEUR_ONCO_IQ_X ✅️ This peer-reviewed ONCO-IQ quiz, developed with the International Urology Cancer Summit (IUCS), offers oncology professionals a quick, high-yield knowledge check in minutes.

🚨 Latest #FDA Approval Update! 🔷 The FDA has granted accelerated approval to zongertinib for unresectable or metastatic non-squamous NSCLC, supported by Beamion LUNG-1, which showed an ORR of 76% (95% CI: 65–85) in untreated HER2-mutant disease.

🚨 Latest #Phase3 Trial Update! 🔷 SystImmune and Bristol Myers Squibb highlight Phase III interim topline results show promising efficacy for izalontamab brengitecan (Iza-bren) in previously treated unresectable or metastatic triple-negative breast cancer.

🚨 Latest #Phase3 Trial Update! 🔷 Bayer’s PEACE-3 trial demonstrates a significant overall survival (OS) benefit with radium-223 dichloride plus enzalutamide in patients with metastatic castration-resistant prostate cancer and bone metastases.

🚨 Latest #FDA Approval Update! 🔷 The US FDA has granted full approval to Pfizer’s BRAFTOVI® in combination with cetuximab (ERBITUX®) and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harbouring a BRAF V600E mutation, based on the global Phase 3 BREAKWATER trial.

✨ Meet Kevin Bambury at ASCO #GU2026 representing ONCOassist! Attending ASCO GU? Let’s connect. #ASCOGU26 #Oncology #CancerCare #DigitalHealth #MedTech #ONCOassist

🚨 Latest #Phase 3 Trial Update! 🔷 The Phase III AXINET (GETNE 1107) trial evaluated axitinib in combination with long-acting Octreotide versus placebo plus Octreotide in patients with advanced extrapancreatic neuroendocrine tumors, assessing progression-free survival (PFS) and clinical benefit.

🚨 Latest #FDA Approval Update! 🔷 U.S. Food and Drug Administration has approved a combination regimen of Venclexta® (venetoclax) plus Acalabrutinib for patients with previously untreated chronic lymphocytic leukemia (CLL), expanding frontline targeted treatment options.

🚨 Latest #FDA Approval Update! 🔷 U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for Roche’s investigational oral selective estrogen receptor degrader (SERD) giredestrant for patients with ESR1-mutated, ER-positive advanced breast cancer.

👉️ Take the Carcinoma Oropharynx ONCO-IQ quiz now - bit.ly/CAOR_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes. ✅️ Apply biomarker-driven decision-making in HPV-associated head and neck cancers

🚨 Latest #Oncology Update! 🔷 Final phase III CONVERT trial results show neoadjuvant CAPOX (Capecitabine & Oxaliplatin) chemotherapy achieved comparable oncologic outcomes to standard chemoradiation in patients with locally advanced rectal cancer and uninvolved mesorectal fascia.